Arcadia Biosciences Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(2,423) | $(9,384) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | (593) | (940) |
| Issuance and offering costs allocated to liability classified options | — | 430 |
| Valuation loss on March 2023 PIPE | — | 6,076 |
| Depreciation | 51 | 71 |
| Lease amortization | 177 | 180 |
| Loss (Gain) on disposal of property and equipment | 2 | (19) |
| Stock-based compensation | 138 | 212 |
| Write-down of inventories | — | 23 |
| Impairment of property and equipment | 36 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (246) | 80 |
| Inventories | 303 | (37) |
| Prepaid expenses and other current assets | 275 | 203 |
| Accounts payable and accrued expenses | (678) | (149) |
| Amounts due to related parties | 17 | (33) |
| Other current liabilities | — | 12 |
| Operating lease liabilities | (269) | (191) |
| Net cash used in operating activities | (3,210) | (3,466) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of property and equipment | 17 | 30 |
| Purchases of property and equipment | (13) | — |
| Proceeds from sale of Verdeca — earn-out received | — | 285 |
| Net cash provided by investing activities | 4 | 315 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE | — | 5,997 |
| Payments of offering costs relating to March 2023 PIPE | — | (497) |
| Proceeds from ESPP purchases | 5 | 5 |
| Net cash provided by financing activities | 5 | 5,505 |
| Net (decrease) increase in cash and cash equivalents | (3,201) | 2,354 |
| Cash and cash equivalents — beginning of period | 6,518 | 20,644 |
| Cash and cash equivalents — end of period | $3,317 | $22,998 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Accrued legal and accounting fees included in offering costs related to March 2023 PIPE | $— | $51 |
| Common stock options issued to placement agent and included in offering costs related to March 2023 PIPE | $— | $212 |
| Proceeds from sale of property and equipment in accounts receivable and other receivables | $12 | $— |
| Purchases of property and equipment in accounts payable and accrued expenses | $13 | $— |
| Warrant and option modifications included in Valuation loss on March 2023 PIPE | $— | $404 |
| Right of use assets obtained in exchange for new operating lease liabilities | $86 | $— |
| Proceeds from sale of Verdeca in accounts receivable and other receivables | $— | $285 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.